Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from HSIC

What to Expect From Henry Schein's Next Quarterly Earnings Report

With Henry Schein expected to release its Q2 earnings next month, analysts project a single-digit profit dip.

Henry Schein (HSIC) Q3 Earnings Analysis: A Medical Stock to Watch?

Henry Schein (HSIC) Q3 Earnings Analysis: A Medical Stock to Watch?

Henry Schein (HSIC) posted solid third-quarter 2023 sales growth and non-GAAP EPS growth despite continued lower sales of PPE products and COVID-19 test kits. In addition, the company’s long-term outlook appears bright, driven by sustained demand for its healthcare solutions and strategic investments. So, is it worth adding this medical…

3 Dental Stocks That Will Keep You Smiling in 2022

3 Dental Stocks That Will Keep You Smiling in 2022

The rebound in demand for dental care services and products with the easing of COVID-19 fears and adoption of advanced technologies in dental care bode well for the dental industry. Therefore, we think the stocks of quality dental companies Dentsply Sirona (XRAY), Patterson Companies (PDCO), and Henry Schein (HSIC) could…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Henry Schein's Return On Capital Employed Overview

Pulled from Benzinga Pro data, Henry Schein (NASDAQ:HSIC) posted Q1 earnings of $186.00 million, an increase from Q4 of 22.25%. Sales dropped to $3.18 billion, a 4.56% decrease between quarters.

Henry Schein Q1 Earnings Beat Street View, Sticks To FY22 Guidance

Henry Schein Inc (NASDAQ:HSIC) posts Q1 FY22 sales of $3.32 billion, beating the consensus of $3.13 billion, up 8.7% Y/Y, including 7.7% internal growth in local currencies, 2.4% growth from acquisitions, and a 1.4% decline related to foreign currency exchange. Q4 internal sales growth in local currencies, excluding personal protective equipment and COVID-19…

4 Medical Distributor Stocks That Deserve a Place in Your Portfolio

The rising demand for drugs and other medical products over the past few years has significantly increased the importance of healthcare distributors. Furthermore, the adoption of advanced and emerging technologies in the healthcare supply chain should help the medical distribution market grow robustly. So, we think the shares of fundamentally…

3 Dental Stocks to Get Your Teeth Into

The dental care market is expected to grow in the coming years, propelled by an increasing geriatric population that is susceptible to dental disorders and people with unhealthy lifestyles that encourage chronic oral diseases. Furthermore, increasing government initiatives to strengthen oral healthcare infrastructure should help the industry grow. So, we…

inkl

Read news from The Economist, FT, and more,
with one subscription

Henry Schein Earnings Conference Call Is Coming Up, Here's What You Need To Know

Henry Schein Earnings Conference Call Is Coming Up, Here's What You Need To Know

Henry Schein (NASDAQ:HSIC) will host a conference call at 10:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Henry Schein (HSIC) Conference Call Follow this link to access the live webcast.

2 Medical Distribution Stocks Surging to New Highs with More Room to Run

2 Medical Distribution Stocks Surging to New Highs with More Room to Run

The healthcare industry is expected to grow significantly, driven by the sustained demand from an aging population, advancements in medical technologies, and increased health awareness among individuals. Thus, we think it could be wise to invest in the fundamentally strong medical distribution stocks AmerisourceBergen (ABC) and Henry Schein (HSIC) with…

5 Best Healthcare Stocks to Buy as a Hedge Against Inflation

5 Best Healthcare Stocks to Buy as a Hedge Against Inflation

The healthcare sector has historically provided a better hedge against inflation than gold because of the inelastic demand for its products and services. Rising healthcare needs of an aging population, integration of advanced technologies, and breakthroughs in clinical trials brighten the sector’s prospects. Therefore, fundamentally-sound and undervalued healthcare stocks Sanofi…

Henry Schein Q4 Topline, Bottom Line Beat Street View, FY22 Outlook Exceeds Consensus

Henry Schein Q4 Topline, Bottom Line Beat Street View, FY22 Outlook Exceeds Consensus

Henry Schein Inc (NASDAQ: HSIC) posts

1 2

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

McKesson Corporation

Cardinal Health Inc

AmerisourceBergen Corporation

Medical – Devices & Equipment

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

388,552 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play